Supplementary Files
How to Cite
Abstract
Hepatitis C is a global health problem affecting around 58 million people worldwide and killing almost 0.29 million in on one year [1]. The world has united to fight against this lethal disease in 2016 with a moto to eliminate hepatitis by 2030. To achieve this goal WHO’s World Health Assembly has set some targets and individual countries have developed their own strategies to achieve those targets [2]. Pakistan has the 2nd highest prevalence of hepatitis C in the world with 5.8% viremia positive patients [3]. Pakistan is amongst the few countries that have been assisted by the Center for Disease Control and Prevention(CDC) to prevent and control Hepatitis[4].
With the availability of Direct Acting Antivirals(DAAs), the whole paradigm of treatment of hepatitis C has changed not only globally but also in Pakistan. However, the patients in Pakistan are unable to gain access to the latest DAAs at the pace, as they are available globally. International guidelines are being updated on regular basis as per global evidence, recommending such combinations which are not readily available to many parts of the world. Hence there is a dire need to develop national guidelines, keeping in consideration the efficacy of the drugs as well as their availability, in the broader canvas of achieving the targets of eliminating Hepatitis set by WHO.
In this context, our consensus guidelines are an effort to fill the gap created because of upgraded scientific evidence and possible combinations available in our part of the world. Furthermore, quite some good research and evidence has also been shared in the literature from Pakistan during last five years (2016-2021). Hence a literature review has also been carried out to update our own epidemiologic data, risk factors and treatment responses to Hepatitis C in Pakistan.
References
Cheemerla, S. and M. Balakrishnan, Global Epidemiology of Chronic Liver Disease. Clin Liver Dis (Hoboken), 2021. 17(5): p. 365-370.
Organization, W.H., Combating hepatitis B and C to reach elimination by 2030: advocacy brief. 2016, World Health Organization.
Gower, E., et al., Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014. 61(1 Suppl): p. S45-57.
Global Viral Hepatitis: Millions of People are Affected. 2021; Available from: https://www.cdc.gov/hepatitis/global/index.htm.
Umar, M., et al., Diagnosis, management and prevention of hepatitis C in Pakistan 2017. Journal of Ayub Medical College Abbottabad, 2017. 28(4 Sup): p. 839-882.
Bostan, N.N., M., Afzal, M.S. Shah, Z.H. Mustafa, Arshad, M. Haider, W., Khan, A.A.1, and S. Asif, Khan, M.R., Ahmad, S.S., Ali, S., Naveed, M and Ahmed, H, Sero-prevalence of Hepatitis B and C Virus from rural areas of northern Punjab (Sargodha District), Pakistan. 2015.
Trickey, A., et al., Importance and contribution of community, social, and healthcare risk factors for hepatitis C infection in Pakistan. The American journal of tropical medicine and hygiene, 2017. 97(6): p. 1920.
Haider, J., et al., Screening of adult dental patients visiting Khyber College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk factors. Pak J Med Sci, 2017. 33(3): p. 615-620.
Khan, A. and J. Qazi, Risk factors and molecular epidemiology of HBV and HCV in internally displaced persons (IDPs) of North Waziristan Agency, Pakistan. JPMA J Pak Med Assoc, 2018. 68(2): p. 165-169.
Salahuddin, N., et al., Five-year Audit of Infectious Diseases at a Tertiary Care Hospital in Karachi, Pakistan. Cureus, 2018. 10(11).
Samo, A.A., et al., Prevalence and risk factors associated with hepatitis B and C in Nawabshah, Sindh, Pakistan. The American Journal of Tropical Medicine and Hygiene, 2021. 104(3): p. 1101.
Jabeen, S., et al., Prevalence and association of HBV and HCV infection with cardiovascular disease risk factors in a peri-urban population. JPMA, 2020. 2019.
Asghar, M.S., et al., A cross-sectional screening survey on the seroprevalence of hepatitis B and hepatitis C amongst the general population of rural districts of Sindh, Pakistan. Arquivos de Gastroenterologia, 2021. 58: p. 150-156.
Dopico, E., et al., Prevalence of Hepatitis C Virus Infection, Genotypes and Subtypes in Migrants from Pakistan in Barcelona, Spain. Infection and Drug Resistance, 2022: p. 4637-4644.
Kazmi, S.A., et al., Kashmiri refugees at the verge of hepatitis B and C epidemic in the State of Azad Jammu and Kashmir, Pakistan. Revista de Saúde Pública, 2022. 56.
Arshad, A. and U.A. Ashfaq, Epidemiology of hepatitis C infection in Pakistan: current estimate and major risk factors. Critical Reviews™ in Eukaryotic Gene Expression, 2017. 27(1).
Al Kanaani, Z., et al., The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analyses. Royal Society open science, 2018. 5(4): p. 180257.
Mahmud, S., Z. Al Kanaani, and L.J. Abu-Raddad, Characterization of the hepatitis C virus epidemic in Pakistan. BMC i
nfectious diseases, 2019. 19(1): p. 1-11.
Arshad, A., et al., Prevalence of transfusion transmissible infections in blood donors of Pakistan. BMC hematology, 2016. 16(1): p. 1-6.
Saeed, M., et al., Silent killers: Transfusion transmissible infections-TTI, among asymptomatic population of Pakistan. J Pak Med Assoc, 2017. 67(3): p. 369-74.
Sultan, S., et al., Multiplex real-time RT-PCR assay for transfusion transmitted viruses in sero-negative allogeneic blood donors: an experience from Southern Pakistan. The Malaysian Journal of Pathology, 2017. 39(2): p. 149.
Naz, A., et al., Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pakistan Journal of Medical Sciences, 2018. 34(5): p. 1204.
Rehman, N., et al., Prevalence of Hepatitis C virus and its risk factors in blood donors in district Peshawar. Pak J Pharm Sci, 2018. 31(1): p. 83-87.
Awan, S.A., A. Junaid, and S. Sheikh, Transfusion transmissible infections: maximizing donor surveillance. Cureus, 2018. 10(12).
Qadir, H., et al., Seroprevalence of Hepatitis B, Hepatitis C, Human Immunodeficiency Virus, syphilis, and malaria among blood donors at tertiary care hospital blood bank. J Pak Med Assoc, 2021. 71(3): p. 897-9.
Saba, N., et al., Seroprevalence of transfusion-transmitted infections among voluntary and replacement blood donors at the Peshawar Regional Blood Centre, Khyber Pakhtunkhwa, Pakistan. Journal of Laboratory Physicians, 2021. 13(02): p. 162-168.
Zahoor, S., et al., Past and Future Perspectives for Hepatitis B and C in Pakistan. Cureus, 2021. 13(8).
Ahmed, R., et al., Frequency of Hepatitis B, C, and Human Immunodeficiency Virus in Blood Donors. Cureus, 2022. 14(6).
Bhatti, M.M., A. Junaid, and F. Sadiq, The prevalence of transfusion transmitted infections among blood donors in Pakistan: A retrospective study. Oman Medical Journal, 2022. 37(3): p. e386.
Gul, A., et al., Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC infectious diseases, 2016. 16(1): p. 1-6.
Mahmud, S., et al., The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction, 2020. 115(7): p. 1244-1262.
Bostan, N., et al., Risk factors involved in spread of HCV in patients from sub urban Rawalpindi and their association with existing genotypes. Tropical Biomedicine, 2016. 33(4): p. 652-662.
Ma, H.-J. and D. Ledward, High pressure/thermal treatment effects on the texture of beef muscle. Meat science, 2004. 68(3): p. 347-355.
Mandhwani, R., et al., Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. Gastroenterology and Hepatology from Bed to Bench, 2020. 13(2): p. 141.
Ullah, A., et al., Hepatitis-C Virus and Cirrhosis: An Overview from Khyber Pakhtunkhwa Province of Pakistan. Viral Immunology, 2020. 33(5): p. 396-403.
Yaqoob, M., et al., Current trends of Hepatitis C virus genotypes and associated risk factors in hemophilia patients in Pakistan. Tropical biomedicine, 2020. 37(4): p. 1000-1007.
Hanif, F.M., et al., Effectiveness of sofosbuvir and ribavirin for eradicating hepatitis C virus in renal transplant recipients in Pakistan: where resources are scarce. Exp Clin Transplant, 2017. 15(Suppl 1): p. 63-67.
Nazir, N., et al., Prevalence of hepatitis-C virus genotypes and potential transmission risks in Malakand Khyber Pakhtunkhwa, Pakistan. Virology journal, 2017. 14(1): p. 1-9.
Yousaf, A., et al., Gender-Specific Frequency Distribution of Hepatitis C Virus Genotypes in Punjab province, Pakistan: A Clinically Significant Descriptive Cross-Sectional Study. Cureus, 2021. 13(8): p. e17480.
Hussain, N., et al., Distribution of hepatitis C virus genotypes in Punjab region, Pakistan, based on a study of 4177 specimens. Infection, Genetics and Evolution, 2021. 91: p. 104811.
Aziz, H., S. Fatima, and M. Faheem, Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunology, 2020. 33(7): p. 507-513.
Rao, J.R., et al., Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan. Archives of Virology, 2021. 166(11): p. 3049-3059.
Khan, M.U., et al., Detection, quantification and genotype distribution of HCV patients in Lahore, Pakistan by real-time PCR. African Health Sciences, 2020. 20(3): p. 1143-1152.
Ahmed, S., et al., Prevalence of Hepatitis C genotypes in District Swabi, Khyber Pakhtunkhwa. Pakistan Journal of Pharmaceutical Sciences, 2018. 31(6): p. 2453-2456.
Ullah, S., et al., Molecular characterization and clinical epidemiology of HCV in District Dir (Lower), Pakistan. VirusDisease, 2018. 29(3): p. 369-374.
Zafar, A., et al., Prevalence and treatment of untypable HCV variants in different districts of Punjab, Pakistan. Viral immunology, 2018. 31(6): p. 426-432.
Ullah, N., et al., Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Brazilian Journal of Biology, 2021. 83.
Bibi, S., et al., Infection control practices in blood banks of Pakistan. Eastern Mediterranean Health Journal, 2019. 25(5): p. 331-340.
Zafar, U., et al., The Frequency of Hepatitis C and its Risk Factors Among Health Care Providers at Tehsil Headquarter Hospital, Hasilpur, Pakistan. Cureus, 2018. 10(8).
Saqib, S., et al., Prevalence and epidemiology of blood borne pathogens in health care workers of Rawalpindi/Islamabad. J Pak Med Assoc, 2016. 66(2): p. 170-3.
Bashir, H.H., et al., Awareness and safe practices of Hepatitis-B and C prevention and transmission among workers of women beauty salons. Pakistan Journal of Medical Sciences, 2022. 38(8).
Qudeer, M.A., et al., Intravenous drug abusers presenting with pseudoaneurysm and other surgical complications in Pakistan. JPMA. The Journal of the Pakistan Medical Association, 2021. 71(1 (A)): p. 556-558.
Sahibzada, K.I., et al., Hepatitis C virus transmission cluster among injection drug users in Pakistan. PloS one, 2022. 17(7): p. e0270910.
Shayan, S.J., R. Nazari, and F. Kiwanuka, Prevalence of HIV and HCV among injecting drug users in three selected WHO-EMRO countries: a meta-analysis. Harm Reduction Journal, 2021. 18(1): p. 1-13.
Masroor, H., et al., Coinfection of Hepatitis B and Hepatitis C Virus in Patients With Human Immunodeficiency Virus. Cureus, 2021. 13(7).
Mir, F., et al., HIV infection predominantly affecting children in Sindh, Pakistan, 2019: a cross-sectional study of an outbreak. The Lancet Infectious Diseases, 2020. 20(3): p. 362-370.
Mir, F., et al., Factors associated with HIV infection among children in Larkana District, Pakistan: a matched case-control study. The Lancet HIV, 2021. 8(6): p. e342-e352.
Kanwal, W. and A. Rehman, High prevalence of vitamin D deficiency in HIV-infected individuals in comparison with the general population across Punjab province, Pakistan. Saudi Journal of Biological Sciences, 2023. 30(1): p. 103484.
Alaei, K., M. Sarwar, and A. Alaei, The urgency to mitigate the spread of hepatitis C in Pakistan through blood transfusion reform. International Journal of Health Policy and Management, 2018. 7(3): p. 207.
Sultan, S., et al., Current trends of seroprevalence of transfusion transmitted infections in Pakistani β-thalassaemic patients. Malays J Pathol, 2016. 38(3): p. 251.
Yasmeen, H. and S. Hasnain, Epidemiology and risk factors of transfusion transmitted infections in thalassemia major: a multicenter study in Pakistan. Hematology, transfusion and cell therapy, 2019. 41: p. 316-323.
Sultan, S., S.M. Irfan, and S. Zaidi, Prothrombotic markers in Thalassemia major patients: A paradigm shift. The Medical Journal of Malaysia, 2018. 73(4): p. 185-189.
Ahmed, S., et al., Thalassemia Patients from Baluchistan in Pakistan Are Infected with Multiple Hepatitis B or C Virus Strains. The American journal of tropical medicine and hygiene, 2021. 104(4): p. 1569.
Hussain, S., et al., Inherited Bleeding Disorders—Experience of a Not-for-Profit Organization in Pakistan. Clinical and Applied Thrombosis/Hemostasis, 2018. 24(8): p. 1241-1248.
Thakur, W., et al., Assessment of Hepatic Profile in Acquired Aplastic Anemia: An Experience From Pakistan. Cureus, 2022. 14(9).
Shafi, S.T., et al., Frequency of Hepatitis C in hospitalized patients with chronic kidney disease. Pakistan journal of medical sciences, 2017. 33(1): p. 18.
Lodhi, A., et al., Profile and predictors of hepatitis and HIV infection in patients on hemodialysis of Quetta, Pakistan. Drug Discov Ther, 2019. 13(5): p. 274-279.
Kiani, I.G., et al., HCV-RNA PCR positivity in HCV antibody negative patients undergoing haemodialysis. Journal of Ayub Medical College Abbottabad, 2018. 30(3): p. 397-400.
Shabbir, U.B., et al., Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Patients Undergoing Maintenance Hemodialysis. Cureus, 2022. 14(5).
Wali, A., et al., Prevalence of tuberculosis, HIV/AIDS, and hepatitis; in a prison of Balochistan: a cross-sectional survey. BMC public health, 2019. 19(1): p. 1-8.
Khan, A., et al., Reuse of syringes for therapeutic injections in Pakistan: rethinking determinants. Eastern Mediterranean Health Journal, 2020. 26(3).
Majid, B., et al., Assessment of knowledge about the risk Factors of chronic liver disease in patients admitted in Civil Hospital Karachi. Cureus, 2019. 11(10).
Bostan, N., et al., Sero-prevalence of Hepatitis B and C Virus from rural areas of northern Punjab (Sargodha District), Pakistan. Tropical Biomedicine, 2016. 33(4): p. 599-607.
Benova, L., S.F. Awad, and L.J. Abu‐Raddad, Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts. Journal of viral hepatitis, 2017. 24(12): p. 1177-1183.
Rahat, M., et al., Episode of Hepatitis C viral infection in the people of Swat, Pakistan. Brazilian Journal of Biology, 2021. 82.
Yasser, F., et al., Possible Mode of Spread of Hepatitis B and Hepatitis C in Chronic Liver Disease Patients Presenting at CMH Lahore Medical College and Institute of Dentistry. Cureus, 2020. 12(2).
Haider, J., et al., Screening of adult dental patients visiting Khyber College of Dentistry, Peshawar for HBV and HCV infections and identifying the associated risk factors. Pakistan journal of medical sciences, 2017. 33(3): p. 615.
Khan, S., S. Shah, and H. Ashraf, Predictive factors for acquiring HCV infection in the population residing in high endemic, resource-limited settings. Journal of Family Medicine and Primary Care, 2021. 10(1): p. 167.
Aslam, N., et al., Diagnosis of hepatitis C in pregnant mothers and its transfer pattern in neonates. Pakistan Journal of Pharmaceutical Sciences, 2017. 30(6).
Jadoon, S.M., et al., Hepatitis B and hepatitis C virus in women with first pregnancy. Journal of Ayub Medical College Abbottabad, 2017. 29(4): p. 614-618.
Israr, M., et al., Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan. PLoS One, 2021. 16(8): p. e0255189.
Ahmad, I., Prevalence of hepatitis B and C viral infection among pregnant women in Peshawar, Pakistan. Hepatitis monthly, 2016. 16(6).
Jilani, K., et al., Frequency and the risk factors of hepatitis C virus in pregnant women; A hospital based descriptive study in Gadap Town Karachi. Pakistan journal of medical sciences, 2017. 33(5): p. 1265.
Khan, A.R., et al., Frequency of acute viral hepatitis A, B, C, and E in pregnant women presenting to Hayatabad medical complex, Peshawar, Pakistan. Cureus, 2022. 14(4).
Gul, F., et al., Knowledge and awareness of Hepatitis B, Hepatitis C, and HIV among pregnant women in Pakistan. The Journal of Infection in Developing Countries, 2022. 16(09): p. 1512-1516.
Afsheen, Z., B. Ahmad, and S. Bashir, Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virology journal, 2017. 14(1): p. 1-6.
Seerat, I., et al., Frequency and associated risk factors of hepatitis B virus and hepatitis C virus infections in children at a hepatitis prevention and treatment clinic in Lahore, Pakistan. Cureus, 2020. 12(5).
Laeeq, S.M., et al., Living-Donor Liver Transplant Follow-Up: A Single Center Experience. Experimental and Clinical Transplantation, 2017. 1: p. 254-257.
Ali, S.M., et al., Oesophageal Varices And Associated Factors In Cirrhotic Patients With Hepatitis C. Journal of Ayub Medical College, Abbottabad: JAMC, 2022. 34(4): p. 834-837.
Rauff, B., et al., PNPLA3 and TM6SF2 genetic variants and hepatic fibrosis and cirrhosis in Pakistani chronic hepatitis C patients: a genetic association study. BMC gastroenterology, 2022. 22(1): p. 401.
Kamran, M., et al., Predictors of Outcome of Cirrhotic Patients Requiring Invasive Mechanical Ventilation: Experience From a Non-Transplant Tertiary Care Hospital in Pakistan. Cureus, 2022. 14(1).
Bhatti, A.B., et al., Clinical profile and treatment of hepatocellular carcinoma: A single-center experience. South Asian Journal of Cancer, 2021. 10(02): p. 76-80.
Kuan, P.F., et al., A systematic evaluation of nucleotide properties for CRISPR sgRNA design. Bmc Bioinformatics, 2017. 18(1): p. 1-9.
Mohammad, S., et al., The frequency of cutaneous manifestations in hepatitis C: a cross-sectional study in a tertiary care hospital in Pakistan. Cureus, 2019. 11(11).
Naqvi, I.H., et al., Restless Leg Syndrome in Patients with Liver Cirrhosis! Its Frequency, Severity, and Correlation. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2021. 20(5): p. 465-472.
Yuan, D., et al., The evaluation of antioxidant and anti-inflammatory effects of Eucommia ulmoides flavones using diquat-challenged piglet models. Oxidative Medicine and Cellular Longevity, 2017. 2017.
Ahmed, N., et al., Effect of HCV on fasting glucose, fasting insulin and peripheral insulin resistance in first 5 years of infection. J Pak Med Assoc, 2016. 66(2): p. 140.
Batool, N., et al., Thyroid dysfunction in non-interferon treated hepatitis c patients residing in hepatitis endemic area. BioMed Research International, 2017. 2017.
Shakeel, U., et al., Double blind, randomised trial to compare efficacy of escitalopram versus citalopram for interferon induced depression in hepatitis C patients. Contemporary Clinical Trials Communications, 2020. 19: p. 100622.
Khuhro, Q., H. Shaikh, and S. Hashmi, Depression trends in Hepatitis-C PCR positive and PCR negative patients. Pakistan Journal of Medical Sciences, 2022. 38(1): p. 162.
Ullah, S., et al., Illness perception about hepatitis C virus infection: a cross-sectional study from Khyber Pakhtunkhwa Pakistan. BMC Infectious Diseases, 2022. 22(1): p. 74.
Falak, S., et al., Prevalence of Vitamin-D deficiency is related to severity of liver damage in Hepatitis-C patients. Pakistan journal of medical sciences, 2020. 36(3): p. 445.
Zuberi, F.F., et al., Non-specific impairment of Lung Function on Spirometery in Patients with Chronic Hepatitis-C. Pakistan Journal of Medical Sciences, 2019. 35(2): p. 360.
Karim, F., et al., Incidence of active HCV infection amongst blood donors of Mardan District, Pakistan. Asian Pacific Journal of Cancer Prevention, 2016. 17(1): p. 235-238.
Khalid, G.G., et al., From risk to care: the hepatitis C screening and diagnostic cascade in a primary health care clinic in Karachi, Pakistan—a cohort study. International Health, 2020. 12(1): p. 19-27.
Iqbal, S., et al., Comparison Of Hepatitis C Antibody Assays And Evaluation Of Agreement Between Hepatitis C Antigen And PCR Results. J Ayub Med Coll Abbottabad, 2022. 34(3).
Waheed, Y., et al., Evaluation of three rapid screening tests for detection of hepatitis C antibodies on mass scale. Critical Reviews™ in Eukaryotic Gene Expression, 2019. 29(1).
Bibi, S., et al., Comparison of dried blood spots with conventional blood sampling for diagnosis of hepatitis b & c through serological and molecular technique; a pilot study. JPMA. The Journal of the Pakistan Medical Association, 2020. 70(7): p. 1214-1219.
Rehman, S.T., H. Rehman, and S. Abid, Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. World Journal of Hepatology, 2021. 13(7): p. 781.
Khan, H.U., et al., Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naïve HCV positive Pakistani patients. Plos one, 2020. 15(4): p. e0231480.
Shakeel, S., et al., Surface-enhanced Raman spectroscopic analysis of centrifugally filtered blood serum samples of hepatitis C patients. Photodiagnosis and Photodynamic Therapy, 2022. 39: p. 102949.
Ali, B., et al., Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients. Pakistan Journal of Medical Sciences, 2022. 38(4Part-II): p. 822.
Capileno, Y.A., et al., Management of chronic Hepatitis C at a primary health clinic in the high-burden context of Karachi, Pakistan. PloS one, 2017. 12(4): p. e0175562.
Iqbal, S., M.H. Yousuf, and M.I. Yousaf, Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World journal of gastroenterology, 2017. 23(44): p. 7899.
Manzoor, S., et al., Efficacy of direct-acting anti-viral therapy on chronic, naïve hepatitis C virus patients of Punjab, Pakistan: a cross-sectional study. Journal of biological regulators and homeostatic agents, 2019. 33(1): p. 105-108.
Sarwar, S., et al., Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. European journal of gastroenterology & hepatology, 2019. 31(8): p. 1035-1039.
Aziz, H., M. Aziz, and M.L. Gill, Analysis of host and viral-related factors associated to direct acting antiviral response in hepatitis C virus patients. Viral Immunology, 2018. 31(3): p. 256-263.
Akhter, T.S., et al., Sofosbuvir for the treatment of hepatitis C genotype 3 infected patients in Pakistan. Journal of Ayub Medical College Abbottabad, 2017. 28(4 Sup): p. 884-889.
Aziz, B., T. Nazar, and S. Akhlaq, The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients. Pakistan journal of medical sciences, 2019. 35(1): p. 101.
Mushtaq, S., et al., Direct‐acting antiviral agents in the treatment of chronic hepatitis C—Real‐life experience from clinical practices in Pakistan. Journal of Medical Virology, 2020. 92(12): p. 3475-3487.
Butt, N., et al., Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan. Cureus, 2019. 11(4): p. e4458.
Butt, N., et al., Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial. Cureus, 2020. 12(1): p. e6537.
Mushtaq, S., et al., Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol, 2020. 11: p. 550205.
Akhter, T.S., et al., Sofosbuvir For The Treatment Of Hepatitis C Genotype 3 Infected Patients In Pakistan. J Ayub Med Coll Abbottabad, 2016. 28(4 Suppl 1): p. S884-s889.
Iqbal, S., M.H. Yousuf, and M.I. Yousaf, Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. World J Gastroenterol, 2017. 23(44): p. 7899-7905.
Butt, N., et al., Efficacy and safety of sofosbuvir-velpatasvir combination in hepatitis C virus-infected Pakistani patients without cirrhosis or with compensated Cirrhosis: A Prospective, Open-label Interventional Trial. Cureus, 2020. 12(1).
Mushtaq, S., et al., Efficacy and safety of generic sofosbuvir plus daclatasvir and sofosbuvir/velpatasvir in HCV genotype 3-infected patients: real-world outcomes from Pakistan. Frontiers in Pharmacology, 2020. 11: p. 550205.
Sheikh, N.T., et al., SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study. Annals of Medicine and Surgery, 2022. 80: p. 104193.
Majid, A., et al., Emergence of resistance against direct acting antivirals in chronic HCV patients: A real-world study. Saudi Journal of Biological Sciences, 2022. 29(4): p. 2613-2619.
Mushtaq, S., et al., Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals. Frontiers in Pharmacology, 2022: p. 1289.
Yulianto, A., Pengaruh Literasi Keuangan Syariah Terhadap Keputusan Penggunaan Produk atau Layanan Lembaga Keuangan Syariah. 2018.
Zahid, H., et al., DAA treatment failures in a low-resource setting with a high burden of hepatitis C infections: a case series. Oxford Medical Case Reports, 2022. 2022(5): p. omac049.
Hanif, F.M., et al., Posttransplant de novo hepatitis c virus infection in renal transplant recipients: its impact on morbidity and mortality. Experimental and Clinical Transplantation, 2017. 1: p. 56-60.
Hanif, F.M., et al., Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan. Experimental and Clinical Transplantation, 2019. 1: p. 198-201.
Cheema, S.U.R., et al., Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis-a prospective interventional clinical trial. BMC nephrology, 2019. 20(1): p. 1-8.
Usman, A., et al., Outcome of Treatment in Children With Chronic Viral Hepatitis C: A Single Centre Study. Cureus, 2022. 14(1).
Butt, N., et al., Efficacy and safety of sofosbuvir and ribavirin for treating chronic hepatitis C, genotype 3: experience of a tertiary care hospital at Karachi, Pakistan. Cureus, 2019. 11(4).
Ahmad, M., et al., Response And Tolerability Of Sofosbuvir Plus Daclatasvir In Elderly Patients With Chronic Hepatitis-C. J Ayub Med Coll Abbottabad, 2019. 31(4): p. 527-9.
Parkash, A., et al., Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C. J Ayub Med Coll Abbottabad, 2022. 34(3): p. 447-451.
Raeder, J., et al., OpenGGCM simulations for the THEMIS mission. Space Science Reviews, 2008. 141(1): p. 535-555.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright (c) 2024 Raza Kazmi